Diet and Weight Reducing Centers (NAICS 812191) — A U.S. Industry Primer

1. Overview

This is the business of helping people lose weight without a doctor: the commercial diet programs, membership "centers," coach-led communities, and branded meal-and-supplement plans Americans have signed up for since the 1960s — think WeightWatchers workshops, the old Jenny Craig storefronts, and Nutrisystem or OPTAVIA meal-and-coaching plans. NAICS (the North American Industry Classification System) code 812191 covers non-medical weight-loss services and the products sold alongside them [4]. The U.S. Census Bureau counts roughly 2,481 employer establishments generating about $2.4 billion in annual receipts [1][2] — a small, highly concentrated industry that sits inside a far larger "weight-loss economy" that market researchers value near $135 billion once prescription drugs, surgery, and medical clinics are added in [5].

The reason this small industry is worth understanding is that it is a live case study in disruption. A single category of medicines — the GLP-1 (glucagon-like peptide-1) receptor agonists sold as Wegovy, Ozempic, and Zepbound — has, in about four years, redirected demand away from behavioral dieting and toward pharmacology. People who once paid for willpower coaching now ask a telehealth provider for a prescription. The result has been a violent shakeout: Jenny Craig liquidated its centers in 2023 [6]; WW International, the parent of WeightWatchers, went through Chapter 11 bankruptcy in 2025 [7][8]; Medifast's revenue roughly halved from its peak [11][12]; and market researchers estimate the legacy commercial-programs segment shrank about 29% in 2023 and 24% in 2024, costing tens of thousands of diet-coaching jobs [5].

So this is less a growth story than a survival-and-adaptation story, and it matters to both public-market and private investors. Public exposure runs through a couple of turnaround "pure plays" and, more directly, through the telehealth firms and drug makers that captured the demand. Private exposure runs through franchisors, local centers, direct-to-consumer food brands, and — the fast-growing frontier — physician-supervised, cash-pay weight-loss clinics that prescribe the very drugs the old centers could not.

2. What it is and how it is structured

NAICS 812191 covers establishments primarily engaged in providing non-medical services to help clients reach or keep a target weight [4]. The typical offering blends individual or group counseling, menu and exercise planning, and regular weigh-ins and body measurement — and, crucially, the sale of weight-reduction products (branded foods, meal replacements, supplements) is often the real profit engine, not the counseling [4].

The main operating models are:

• Center-based programs with recurring memberships, appointments, and product sales.
• Franchise systems, where local owners operate centers and the franchisor earns fees and royalties.
• Coach-led communities, often supported by digital tools and delivered food or supplements.
• Hybrid subscription programs combining in-person or virtual coaching with an app and product sales.

The defining word is non-medical, and what the code excludes is as important as what it includes:

• Medical or surgical weight reduction — physician-supervised programs, bariatric surgery, and clinics that prescribe GLP-1 drugs — is classified in Sector 62, Health Care and Social Assistance (e.g., offices of physicians), not here [4]. This is the single most important scope point in 2026: the fastest-growing part of "weight loss" has migrated out of this NAICS code.
• Physical fitness and recreational sports centers → NAICS 713940.
• Health resorts and spas that provide lodging → NAICS 721110.
• Diet-food manufacturing → food manufacturing (NAICS 311xxx); diet-drug manufacturing → pharmaceutical preparation (NAICS 325412); dispensing those drugs → pharmacies and drug retailers.
• Direct-selling coach-distributor meal-replacement models (the OPTAVIA and Herbalife style) are often captured under other direct selling (NAICS 454390) rather than here.

Ownership is layered and barbell-shaped. A few large, nationally branded operators control marketing, curricula, technology, and products; many small independent centers and franchisees control the local customer relationship. Federal data show about 1,376 firms running roughly 2,481 establishments [1][2] — most firms are single-unit, but revenue is dominated by a handful of brands (see concentration below). Importantly, the Census concentration data identify firms and revenue shares but do not name the largest companies [2].

3. How big it is

Our federal figures come from the 2022 Economic Census, 2023 County Business Patterns (CBP), and the Small Business Administration (SBA) size-standard table. The years are not directly comparable.

Two readings stand out. First, concentration is high: the top four firms take nearly two-thirds of revenue and the top 50 take over three-quarters [2] — consistent with a market long ruled by a few national brands. The HHI itself is suppressed, so no single measure of market power is published [2]. Second, pay is low — roughly $32,200 per employee on average [1] — reflecting a workforce of part-time counselors and center staff.

The undercount caveat here is large and runs two ways. (1) These figures capture only the non-medical commercial slice. They exclude the medical weight-loss and GLP-1 economy now sitting in health-care Sector 62 (a cash-pay clinic market independently projected toward ~$1.5 billion by 2030 [20]); the prescription obesity-drug market, whose U.S. sales run into the tens of billions (Wegovy alone tracked toward roughly $13 billion in 2025 [18]); and direct-selling and telehealth/app subscriptions that classify under retail, direct selling, or software. (2) CBP and Economic Census size tables cover employer establishments with payroll, so nonemployer businesses, very small operators, and some home-based or contractor-led activity are missed [1][2].

So the ~$2.4 billion "industry" is best read as the shrinking, classically defined commercial-diet segment — not the total money Americans spend to lose weight, which researchers put near $135 billion in 2025 [5]. And the physical-center count is a moving target: with Jenny Craig's storefronts gone (2023) and WeightWatchers having shifted away from in-person workshops, the 2022–2023 establishment count likely overstates the storefront footprint that survives today [6][8].

4. Investable universe

No public company reports only NAICS 812191 revenue, so public-company revenue should never be treated as 812191 market share. The two remaining public "pure plays" are turnaround situations; the more direct exposure to where the demand went comes from adjacent telehealth firms and the drug makers. Tickers and figures are kept here (and in Section 10), not in the prose above.

Public companies with the closest exposure

Adjacent public companies capturing the same customer

Major private / other owners (identified from company and regulatory materials; the Census does not confirm any of these are among the largest four firms)

• Wellful (owned by private-equity firm Kainos Capital) — portfolio includes Nutrisystem; Wellful also acquired the Jenny Craig brand in 2023 and relaunched it as a direct-to-consumer business [22][23]. The ~500-center Jenny Craig storefront chain that liquidated in 2023 is gone [6].
• Diet Center Worldwide (owned by Health Management Group) — in-center and online programs offered via single- and multi-unit franchises [34].
• Lindora — a medically oriented weight-management brand that Next Health Management Group acquired from Xponential Fitness in 2025 [24]; because it is medical, it sits outside the strict non-medical 812191 definition.
• Noom, Ro, Found, Calibrate — venture- and growth-backed telehealth/behavioral weight platforms [26]; adjacencies rather than core 812191 operators.
• Thousands of independent, cash-pay medical weight-loss clinics — the fragmented, fast-growing private frontier.

There is no pure-play ETF (exchange-traded fund) for this industry; public exposure comes through the individual names above or broad consumer-discretionary and health-care funds.

5. How the money works

Owners monetize through a few distinct models, and the mix has shifted sharply:

• Subscriptions / recurring memberships (the WeightWatchers model). Revenue is subscribers × price. Economics live or die on retention (churn), customer acquisition cost (CAC) versus lifetime value (LTV), and strong Q1 seasonality (New Year sign-ups). It is a software-like model layered on coaching.
• Product sales / branded food (the old Jenny Craig and Nutrisystem model). Historically the profit came less from counseling than from selling proprietary meals, shakes, and supplements at a markup. Gross margin on product — not counseling fees — funded the storefronts. This raises revenue per customer but adds inventory, shipping, food-cost, and working-capital risk.
• Direct selling / coach-distributor model (Medifast's OPTAVIA, Herbalife). Independent "coaches" or distributors both use and sell the products. The key operating metrics are the number of active earning coaches and revenue per coach — both of which fell sharply as GLP-1 drugs pulled customers away (Medifast's coach count fell from ~25,400 to ~22,800 across the first half of 2025) [12][13].
• Franchise model. The franchisor is relatively asset-light — collecting initial fees, royalties, advertising contributions, and product revenue — while the franchisee carries the lease, staffing, and execution risk. As an illustration of clinic-scale franchise economics, the Lindora medical-wellness brand has been quoted at a total investment of roughly $578,000–$1,005,000 with a $120,000 franchise fee [25].
• Cash-pay clinical fees (the new medical model, adjacent to 812191). Physician-supervised clinics charge monthly management fees of roughly $300–$1,500 per patient, usually out of pocket because insurance coverage for weight management is thin [20]. Margins are attractive because the fee is for oversight; the drug cost is often a pass-through.

The strategic pivot across the survivors is the same: wrap a subscription or service fee around access to GLP-1 drugs. WeightWatchers reports a fast-growing "clinical" line — clinical subscribers rose ~42% even as total subscribers fell [9] — and Medifast routes qualified customers to prescriptions via its LifeMD stake [14]. The value the owner captures is the coaching-and-adherence wrapper, not the molecule.

Useful operating metrics investors track (federal statistics provide none of these for 812191, so they come from filings, franchise disclosure documents, or private diligence): member retention and revenue per active member; comparable-center sales and appointment utilization; CAC, LTV, and CAC payback; product gross and contribution margin and inventory turnover; site-level EBITDA (earnings before interest, taxes, depreciation, and amortization); franchisee openings, closures, and cash returns; and, for medical adjacencies, clinician productivity, prescription retention, and medication mix.

6. Demand drivers

• Obesity and diabetes prevalence. The Centers for Disease Control and Prevention (CDC) reported adult obesity prevalence of 40.3% for August 2021–August 2023, from measured national health data, and its 2024 maps showed prevalence of at least 25% in every state and territory reported [27][28]. This is a structural, long-run tailwind for anything labeled weight loss.
• The GLP-1 shock (the dominant force since ~2022). Highly effective injectables deliver roughly 15–20% body-weight loss versus the low-single-digit results typical of behavioral programs. That efficacy gap has reset consumer expectations and pulled spending toward drugs and the clinics that prescribe them, shrinking demand for stand-alone behavioral programs [5]. It is simultaneously the industry's biggest threat and, for players who integrate the drugs, its biggest opportunity — creating new demand for nutrition counseling, muscle preservation, medication adherence, and weight-maintenance services.
• Insurance and employer coverage. Whether commercial plans, employers, and Medicare/Medicaid cover GLP-1 drugs for obesity swings demand between cash-pay clinics and the broader market, and employer or health-plan partnerships can lower customer-acquisition cost.
• Consumer discretionary spending and seasonality. Sign-ups spike in January and after summer; recessions and drug prices both pressure discretionary program spending.
• Culture, social media, and body-image trends — the historical engine of fad-diet boom-bust cycles.

7. Regulation

The centers themselves are lightly regulated as non-medical businesses, and the industry's first regulatory issue is classification: a non-medical center must not drift into diagnosis, treatment, or prescribing, which requires licensed professionals and would move the business into Health Care and Social Assistance [4]. Beyond that, several agencies and rules shape the industry:

• Federal Trade Commission (FTC). The long-standing watchdog for deceptive weight-loss advertising; efficacy and testimonial claims must be truthful, non-misleading, and backed by "competent and reliable scientific evidence" [29]. The FTC also governs auto-renewal / "negative-option" subscriptions and endorsement/influencer disclosures — relevant to every membership model — and, for franchisors, requires a Franchise Disclosure Document (FDD) to be given to a prospective franchisee at least 14 days before signing or paying [31].
• Food and Drug Administration (FDA). Regulates the dietary supplements and meal-replacement products these firms sell; under the Dietary Supplement Health and Education Act (DSHEA), the FDA generally does not pre-approve structure/function claims, but labels must carry disclaimers and disease-treatment claims can trigger drug regulation [30]. The FDA also regulates the GLP-1 prescription drugs the industry is racing to attach to: its rulings on drug shortages and compounding directly affect telehealth players who sold lower-cost compounded semaglutide, and when the FDA judged the shortage resolved it restricted copying of the approved drugs, squeezing that revenue line [17][33].
• State medical boards and telehealth law. Because prescribing is medical practice, firms adding GLP-1 access must work through licensed clinicians and affiliated medical groups (navigating "corporate practice of medicine" rules and state telehealth licensure). This is why behavioral brands partner with or acquire telehealth providers rather than prescribe directly.
• Health-data privacy. The Health Insurance Portability and Accountability Act (HIPAA) can apply to covered medical providers, while the FTC's Health Breach Notification Rule reaches many health apps and personal-health-record businesses that fall outside HIPAA [32].

Notably, there is generally no professional licensure requirement for a "diet counselor" or center coach (unlike registered dietitians) — a low barrier that has historically let fad operators enter easily.

8. Competitive dynamics and consolidation

The industry has always been cyclical and concentrated — a few big brands, punctuated by fad-diet booms and busts. The reported ratios show a concentrated revenue tail (top four firms 63.5% of receipts, top 50 76.8%), even as local centers and franchisees stay fragmented because the federal data cover establishments rather than consumer-facing brands and omit nonemployer activity [1][2]. The GLP-1 era turned an ordinary cycle into a structural shakeout:

• Exits and distress. Jenny Craig filed for liquidation and closed its ~500 centers in 2023 [6]. WW International filed a prepackaged Chapter 11 in May 2025 and emerged about a month later, eliminating ~$1.15 billion of debt (about 70% of its load) and relisting on Nasdaq [7][8]. Medifast's revenue fell roughly 37% year-over-year and its active-coach count dropped by thousands [12][13].
• Convergence with telehealth. Behavioral brands are buying their way into medicine (WeightWatchers acquired the telehealth provider Sequence in 2023; Medifast took a $20 million stake in LifeMD [14]), while telehealth natives (Hims & Hers, Ro, LifeMD, Noom) attack from the clinical side.
• Disintermediation by the drug makers. Novo Nordisk and Eli Lilly have launched direct-to-patient channels (NovoCare, LillyDirect), threatening to bypass both the old programs and the telehealth middlemen [18][19].
• Cross-code roll-ups. Private capital is combining branded weight-management assets, digital health, and medical clinics even when their formal NAICS codes differ: Kainos built the Wellful platform around Nutrisystem and Jenny Craig, and Next Health acquired Lindora from a public fitness franchisor [22][23][24].

Scale advantages accrue to brand recognition (lower CAC), technology and data, national product sourcing, and the clinical/legal infrastructure for medical adjacencies. Local advantages are trust, community, and owner involvement. The strongest model may be a hybrid: a recognizable brand and digital platform combined with local or human support.

9. Risks

• Substitution risk (existential). GLP-1 drugs directly replace the core value proposition of a behavioral program; researchers estimate the commercial-programs segment shrank ~29% in 2023 and ~24% in 2024 [5]. Firms that don't integrate the drugs face structural decline.
• Two-sided drug-economics risk. Falling GLP-1 prices, broader insurance coverage, or cheap oral GLP-1 pills could either crush behavioral programs further or expand the pool of customers who need an adherence wrapper — the direction is genuinely uncertain and is a forward-looking judgment, not a settled fact.
• Compounding crackdown. Telehealth revenue tied to compounded semaglutide is exposed to FDA shortage/compounding rulings [17][33].
• Retention, CAC, and seasonality. Weight-loss customers are notoriously hard to keep — weight regain undermines lifetime value — demand is concentrated in a few months, and digital and celebrity-led marketing can make growth expensive.
• Regulatory and litigation risk. FTC scrutiny of claims and auto-renewal cancellation; franchise-disclosure obligations; state telehealth and prescribing rules [29][31][33].
• Privacy risk. Weight, medication, and biometric data are sensitive and can trigger FTC or state enforcement [32].
• Supply dependence and disintermediation. Firms that resell GLP-1s depend on Novo and Lilly for supply and pricing and risk being bypassed by those same suppliers.
• Financial and franchisee risk. WW's bankruptcy shows how even a recognizable brand can face severe leverage; weak local operators, high rent, or closures reduce royalties and reach [8].
• Measurement risk. Public-company revenue often bundles products, telehealth, and international operations and should not be read as 812191 market share.

10. How to invest and the outlook

Public routes.

• Pure-play turnarounds: WW International (Nasdaq: WW) — a restructured, lower-debt company betting on a clinical and women's-health pivot; and Medifast (NYSE: MED) — net cash, no debt, but a shrinking coach base mid-transition to a GLP-1-integrated model [8][11][12][13]. Herbalife (NYSE: HLF) offers broader direct-selling nutrition exposure, only about half of it weight management [21].
• Bet on where demand went: telehealth — Hims & Hers (NYSE: HIMS) and LifeMD (Nasdaq: LFMD) [14][15]; and the drug makers who are the clearest winners — Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) [18][19]. These are different business models, not interchangeable 812191 companies. There is no dedicated ETF; diversified consumer or health-care funds give indirect exposure.

Private routes.

• Own a center or clinic. Franchise a branded center (e.g., Diet Center [34]) or a medical-wellness clinic (Lindora's quoted economics run ~$578K–$1M all-in [25]), or open an independent cash-pay weight-loss clinic charging $300–$1,500/month per patient [20].
• Back a platform. Venture and growth equity in Noom, Ro, Found, Calibrate, and similar [26]; buyout exposure via Nutrisystem's owner (Kainos Capital / Wellful) [22].
• Lend or roll up. Lend against recurring subscriptions, franchise royalties, or contracted health-plan revenue; or acquire local centers and clinics in a fragmented, roll-up-friendly landscape.

Diligence should separate non-medical center revenue from products, digital subscriptions, medical care, and prescription-drug revenue, then examine cohort retention, CAC payback, site-level margins, franchisee cash returns, claims substantiation, licensing, and balance-sheet liquidity. Franchise investors should read the FDD and independently verify closure, litigation, and earnings claims [31].

Outlook (forward-looking judgment). The classically defined, non-medical diet-center model is in structural decline, and the federal data understate how fast the money is migrating into health care. But the demand to lose weight has never been larger — a market valued near $135 billion in 2025 [5], resting on obesity prevalence above 40% [27]. The likely winners are operators that stop fighting GLP-1 drugs and instead wrap coaching, adherence, nutrition, muscle-preservation, and maintenance services around them — and that find adjacent categories (women's health, post-drug maintenance) to grow into. The likely losers are businesses dependent on one-off memberships, unsupported claims, or product sales without durable retention. Near-term swing factors to watch: the price trajectory of GLP-1 drugs; approval and uptake of oral GLP-1 pills; insurance and Medicare coverage decisions; FDA compounding rules; WeightWatchers' turnaround execution; and whether Novo and Lilly's direct-to-patient channels disintermediate the intermediaries entirely. For most investors, the sharper way to play this theme is the drug makers and telehealth platforms; the pure-play diet companies are higher-risk, self-help turnarounds.

---

Sources

1. U.S. Census Bureau, County Business Patterns: 2023, NAICS 812191 (establishments, employees, payroll). https://www.census.gov/data/datasets/2023/econ/cbp/2023-cbp.html
2. U.S. Census Bureau, 2022 Economic Census — Concentration of Largest Firms (receipts, firms, CR4/CR8/CR20/CR50; HHI suppressed), NAICS 812191. https://data.census.gov/table/ECNSIZE2022
3. U.S. Small Business Administration, Table of Size Standards, NAICS 812191 ($27.5 million average annual receipts), 2023. https://www.sba.gov/document/support-table-size-standards
4. U.S. Census Bureau, 2022 NAICS: 812191 Diet and Weight Reducing Centers (non-medical scope; medical/surgical weight reduction classified in Sector 62). https://www.census.gov/naics/?details=81219&input=81219&year=2022
5. Marketdata Enterprises / GlobeNewswire, "U.S. Weight Loss Market Status & Forecast Report 2025-2026: GLP-1 Boom Triggers Major Industry Shift… $135 Billion Diet Market," 2026. https://www.globenewswire.com/news-release/2026/03/10/3253070/28124/en/U-S-Weight-Loss-Market-Status-Forecast-Report-2025-2026-GLP-1-Boom-Triggers-Major-Industry-Shift-as-Medicalized-Programs-Disrupt-the-135-Billion-Diet-Market.html
6. CNN Business, "Jenny Craig is going out of business," 2023. https://www.cnn.com/2023/05/05/business/jenny-craig-shutdown/index.html
7. Financier Worldwide, "WeightWatchers files for Chapter 11 to reduce $1.15bn debt," 2025. https://www.financierworldwide.com/weightwatchers-files-for-chapter-11-to-reduce-115bn-debt
8. U.S. Securities and Exchange Commission, WW International 2025 Form 10-K (reorganization, relisting). https://www.sec.gov/Archives/edgar/data/105319/000119312526107176/ww-20251231.htm
9. StockTitan, "Weight Watchers… Fourth Quarter and Full Year 2025" (subscribers ~2.8M, clinical +42%, 2026 guidance ~$620–635M), 2026. https://www.stocktitan.net/news/WW/weight-watchers-announces-fourth-quarter-and-full-year-2025-c398fxu68jbx.html
10. WeightWatchers, "WeightWatchers Announces Third Quarter 2025 Results" (Q3 revenue ~$172M, −11%), 2025. https://finance.yahoo.com/news/weightwatchers-announces-third-quarter-2025-120000697.html
11. U.S. Securities and Exchange Commission, Medifast 2025 Form 10-K (product sales ~96.4% of revenue). https://www.sec.gov/Archives/edgar/data/910329/000162828026008656/med-20251231.htm
12. StockTitan, "Medifast Q2 Revenue Falls 37% as GLP-1 Drugs Impact Weight Loss Market" (Q2 2025 revenue $105.6M, ~22,800 coaches), 2025. https://www.stocktitan.net/news/MED/medifast-announces-second-quarter-2025-financial-6lts75qxsees.html
13. Medifast, Inc., "First Quarter 2025 Financial Results" (Q1 revenue $115.7M, ~25,400 coaches, $162.7M cash, no debt), 2025. https://ir.medifastinc.com/news/news-details/2025/Medifast-Announces-First-Quarter-2025-Financial-Results/default.aspx
14. LifeMD, Inc., Form 8-K on Medifast $20M investment / GLP-1 telehealth partnership, 2023. https://www.sec.gov/Archives/edgar/data/948320/000149315223044648/ex99-1.htm
15. Fierce Healthcare, "Hims & Hers projects weight loss business to hit $725M in 2025," 2025. https://www.fiercehealthcare.com/health-tech/hims-hers-bullish-weight-loss-business-despite-glp-1-market-shift
16. U.S. Securities and Exchange Commission, Hims & Hers Health 2025 Form 10-K. https://www.sec.gov/Archives/edgar/data/1773751/000177375126000022/hims-20251231.htm
17. STAT, "Hims & Hers Health addresses scrutiny of GLP-1 compounding," 2026. https://www.statnews.com/2026/02/23/him-hers-earnings-2026-outlook-compounded-semaglutide/
18. S&P Global Market Intelligence, Novo Nordisk Wegovy U.S. sales (~$13B, 2025) / weight-loss-drug race, 2025. https://www.spglobal.com/market-intelligence/en/news-insights/research/2025/08/eli-lilly-set-to-leapfrog-novo-nordisk-in-weight-loss-drug-race
19. Axios, "GLP-1 brands: Eli Lilly is the new king of weight loss drugs," 2025. https://www.axios.com/2025/10/21/glp-1-brands-obesity-eli-lilly-weight-loss-drugs
20. Grand View Research, "U.S. Medical Weight Loss Clinics Market… Worth $1.5 Billion by 2030" (cash-pay $300–$1,500/month fees), 2025. https://www.grandviewresearch.com/industry-analysis/us-medical-weight-loss-clinics-market-report
21. Herbalife Ltd., 2025 Form 10-K (weight management ~54.5% of sales). https://ir.herbalife.com/sec-filings/all-sec-filings/content/0001193125-26-057113/hlf-20251231.htm
22. Kainos Capital, "Kainos Capital to Acquire Nutrisystem" (Wellful platform), 2020. https://kainoscapital.com/news-press/kainos-capital-to-acquire-nutrisystem/
23. Wellful, Inc. / PR Newswire, "Wellful Acquires Jenny Craig Brand," 2023. https://www.prnewswire.com/news-releases/wellful-inc-acquires-jenny-craig-brand-expanding-its-portfolio-of-leading-health-and-wellness-brands-301870224.html
24. Xponential Fitness / U.S. Securities and Exchange Commission, "Xponential Announces Divestiture of Lindora" (to Next Health Management Group), 2025. https://www.sec.gov/Archives/edgar/data/1802156/000119312525208250/d941595dex991.htm
25. Franchise Gator, "Lindora: Weight Loss Clinics and Diet Programs Franchise Cost, Fees" (~$578K–$1M investment, $120K fee), 2026. https://www.franchisegator.com/franchises/lindora/
26. Associated Press, "Ro CEO Charts Growth Past Sexual Health Roots to Obesity and Beyond," 2023. https://apnews.com/article/e3ec6a6246917e08af1f28a213945e86
27. Centers for Disease Control and Prevention, "Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023" (adult obesity 40.3%), 2024. https://www.cdc.gov/nchs/products/databriefs/db508.htm
28. Centers for Disease Control and Prevention, "2024 Adult Obesity Prevalence Maps," 2025. https://www.cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html
29. Federal Trade Commission, "Health Products Compliance Guidance," 2022. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
30. U.S. Food and Drug Administration, "Structure/Function Claims" (DSHEA), 2026. https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/structurefunction-claims
31. Federal Trade Commission, "A Consumer's Guide to Buying a Franchise" (FDD 14-day rule), 2026. https://www.ftc.gov/business-guidance/resources/consumers-guide-buying-franchise
32. Federal Trade Commission, "Health Breach Notification Rule," 2024. https://www.ftc.gov/legal-library/browse/rules/health-breach-notification-rule
33. U.S. Food and Drug Administration, "FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize," 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
34. Diet Center (Health Management Group), "Franchise Information," 2026. https://www.dietcenter.com/franchise-information